- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Antipsychotic Treatment Options In Schizophrenia

Virtual Event – Antipsychotic Treatment Options In Schizophrenia
The treatment of schizophrenia has evolved over the past half-century primarily in the context of antipsychotic drug development. In addition to reviewing the evolution of antipsychotic treatments for schizophrenia, in this virtual live event the speakers will discuss definitions of adherence and review possible reasons for nonadherence, as well as compare evidence supporting oral and long-acting injectable antipsychotics. Lastly, the speakers will explore potential communication strategies for clinicians to assess patient adherence and discuss alternative interventions.
Featuring
-
Julleah Johnson, PhD (OPDC)
Senior Medical Science Liaison
-
Roger Sommi, PharmD, FCCP, BCPP
Associate Dean, UMKC School of Pharmacy – University of Missouri
Roger Sommi, PharmD, FCCP, BCPP is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. Julleah Johnson, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
Register
This event registration is closed.